RNAi Licenses MetaCore From GeneGo

GeneGo, Inc., a leading provider of software and databases for systems biology, announced that RCL has licensed MetaCore for its RNA interference drug discovery efforts. MetaCore is an integrated platform for the analysis of different types of experimental data in drug discovery. MetaCore applies a proprietary, manually curated, human protein interaction and pathway database to drug discovery. The flexible database architecture enables straightforward integration of in house and third party software and databases. MetaCore also has easy to use software for building, visualization and analysis of tissue specific biological networks with and without experimental data. "We looked at several systems biology packages and found that MetaCore suited our needs the best," said Mr.Yukikazu Natori, Chairman of RNAi. "The system is flexible for customization, and the GeneGo team is open minded for collaborative development. We needed a flexible partner that was willing to integrate with our current siRNA technology." "We welcome RCL as our first Japanese customer," said Tatiana Nikolskaya, Ph.D., President and CSO of GeneGo. "RCL has built an impressive and unique technology portfolio in the RNA interference area. Their findings are very synergistic with pathway analysis of complex diseases we are working on. We consider this agreement as the first step in long term collaboration in the intersection of these two exciting technologies."